Dual Therapy for Chronic Migraine: Atogepant Plus Botox Study

Research Summary

A recent study published in Cephalalgia explored the effects of combining atogepant with onabotulinumtoxinA for chronic migraine prevention. Conducted over 24 weeks with 75 participants, the study found that adding atogepant to onabotulinumtoxinA was safe and generally well-tolerated. Treatment-emergent adverse events were reported in 65% of participants, with constipation (16%), nausea (13%), and urinary tract infections (8%) being the most common. Clinically meaningful reductions in monthly migraine days were observed, with a 54% to 62% responder rate for a ≥50% reduction in migraine days. These results suggest benefits in combining treatments targeting different physiological mechanisms.

Study Details

📄 Title: Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

👥 Research Team: Rothrock J et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2026 Apr

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.